Lineage Cell Therapeutics Price Target Cut to $3.00/Share From $5.00 by Maxim Group

Dow JonesJan 10 13:36 ET · Ratings

Lineage Cell Therapeutics Is Maintained at Buy by Maxim Group

Dow JonesJan 10 13:36 ET · Ratings

Lineage Is Maintained at Neutral by Mizuho

Dow JonesJan 8 11:28 ET · Ratings

Mizuho Securities Maintains Lineage(LINE.US) With Hold Rating, Cuts Target Price to $67

Moomoo NewsJan 8 08:34 ET · Ratings

Express News | Lineage Inc : UBS Cuts Target Price to $64 From $75

ReutersJan 6 09:13 ET

D. Boral Capital Maintains Buy on Lineage Cell Therapeutics, Maintains $2 Price Target

BenzingaJan 3 09:07 ET · Ratings